Provided by Tiger Trade Technology Pte. Ltd.

LUYE PHARMA

1.830
-0.035-1.88%
Volume:29.03M
Turnover:52.75M
Market Cap:7.31B
PE:9.87
High:1.860
Open:1.860
Low:1.800
Close:1.865
52wk High:3.830
52wk Low:1.730
Shares:4.00B
HK Float Shares:4.00B
Volume Ratio:1.36
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.185
ROE:4.27%
ROA:2.18%
PB:0.40
PE(LYR):9.87
PS:1.02

Loading ...

Movement Alert|Luye Pharma Rises 5.29% in Regular Trading, Convertible Bond Redemption and Clinical Progress Fuel Rally

Market Focus
·
Jul 14

Movement Alert|Luye Pharma Rises 5.73% in Regular Trading, Multiple Catalysts Including Bond Redemption and Clinical Milestones Boost Sentiment

Market Focus
·
Jul 13

Shandong Boan Says China CDE Accepts IND Filing for Ba1203 Masked Anti-pd-1/il-2 Fusion Protein

Reuters
·
Jul 08

Luye Pharma Completes Early Redemption of $180 Million Convertible Bonds

MT Newswires Live
·
Jul 07

LUYE PHARMA Successfully Completes Early Redemption of Outstanding US$180 Million Convertible Notes Due 2028

Stock News
·
Jul 06

Luye Pharma Completes Early Redemption of US$180.00 Million 6.25% Convertible Bonds

Bulletin Express
·
Jul 06

Movement Alert|Luye Pharma Rises 5.91% in Regular Trading, UBS Increases Stake Amid Innovative Drug Sector Rebound

Market Focus
·
Jul 03

Movement Alert|Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure

Market Focus
·
Jun 30

Luye Pharma: Shareholders Pass All AGM Resolutions with Overwhelming Majority, Re-Elect Directors and Renew Key Mandates

Bulletin Express
·
Jun 26

Luye Pharma Shareholders Back Share Issuance Mandate at AGM Poll

Reuters
·
Jun 26

Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM

Reuters
·
Jun 22

Luye Pharma Group Drug Meets Main Goal of Phase 2 Study

MT Newswires Live
·
Jun 17

Daily Insight into Hong Kong Stocks: DeepSeek Secures $50 Billion Funding, Yum China Acquires Full Ownership of Pizza Hut in Mainland China

Stock News
·
Jun 17

LUYE PHARMA's Novel Drug LY03015 Shows Positive Phase II Results in China for Tardive Dyskinesia

Stock News
·
Jun 16

Luye Pharma reports strong Phase 2 data for first-in-class TD therapy LY03015, sets stage for global Phase 3

Bulletin Express
·
Jun 16

Luye Pharma says LY03015 meets primary endpoint in China Phase 2 tardive dyskinesia trial

Reuters
·
Jun 16

TransThera Sciences names Sun Delong chief operating officer

Reuters
·
Jun 12

Luye Pharma Group's Bond Buyback Undersubscribed

MT Newswires Live
·
Jun 12

Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

Reuters
·
Jun 11

Luye Pharma Completes $180 Million Convertible Bond Sale

MT Newswires Live
·
Jun 11